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Abstract
Cervical cancer (CC) is one of the acquired immunodeficiency syndrome (AIDS) defining diseases and the human immunodeficiency
virus (HIV) infection is thought to relate with increased acute toxicity of chemoradiotherapy (CRT).
We investigated the effect of HIV status in the incidence of neutropenia associated with cisplatin-based CRT for CC and its impact
in treatment completion.
This is a single-center retrospective cohort study. Data collection was performed for all the consecutive stage Ib-IV CC women
treated with cisplatin-based CRT from 2012 to 2016, and with known HIV status.
Sixty-one patients were included, 6 were HIV+. HIV+ patients had a higher risk of neutropenia at any cycle during cisplatin CRT
[adjusted odds ratio (OR) 7.3, 95% confidence interval (95% CI) 1.02–52.3; P= .05]. Despite the absolute differences, mean
neutrophil count was nonsignificantly lower in HIV+ women, both at baseline [4455/mL (interquartile range, IQR: 1830–6689) vs 6340
(IQR: 1720–18,970) for HIV, P= .98] and at the end of treatment [1752/mL (IQR: 1100–2930) vs 3147/mL (IQR: 920–18,390) in
HIV; P= .06]. Moreover, when considering the effect of time, CRT seems to induce a consistent drop of neutrophils in both groups
(P= .229). No febrile neutropenia events occurred.
In HIV+women, there weremore CT cycle delays (P= .013), patients weremore prone to use granulocyte colony-stimulating factor
(G-CSF; HIV+ 40.0% vs HIV 4.0%; P= .04) and less likely to complete at least 5 cycles of cisplatin (P= .02). All patients received
adequate dose of pelvic RT, regardless of HIV status.
HIV+ patients have a significantly increased risk of neutropenia during CRT treatment for CC and are less likely to complete
chemotherapy with cisplatin.
Abbreviations: AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, AST = aspartate aminotransferase,
AUC = area under the curve, BT = brachytherapy, CC = cervical cancer, CHLN = Centro Hospitalar Lisboa Norte, CI = Confidence
interval, CRT = Chemoradiotherapy, CT = Chemotherapy, CTCAE v4.0 = common terminology criteria for adverse events v 4.0,
EBRT = external beam radiotherapy, eGFR = estimated glomerular filtration rate, FIGO = International Federation of Gynecology and
Obstetrics, G-CSF = granulocyte colony-stimulating factor, HIV = human immunodeficiency virus, HPV = human papilloma virus,
ICRU = International Commission on Radiation Units and Measurements, II = integrase inhibitor, IQR = interquartile rage, MDRD =
Modification of diet in renal disease, NCCN = National comprehensive cancer network, NNTRI = non-nucleoside reverse
transcriptase inhibitor, NTRI = nucleoside reverse transcriptase inhibitor, OR = odds ratio, OS = overall Survival, PALOP =
Portuguese African Speaking Countries, RT = radiotherapy, SCCA = squamous cell carcinoma of the anal canal, WPRT = whole
pelvic radiotherapy.
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active antiretroviral therapy (ART) in contrast with Kaposi
sarcoma or non-Hodgkin lymphoma.[1,2] Women with HIV have
a higher prevalence of infection by human papilloma virus (HPV)
and a higher tendency to develop persistent infections.[3] In fact,
CC is considered an acquired immunodeficiency syndrome
(AIDS) defining disease, and all HIV-positive (HIV+) women
with CC have AIDS, regardless of other characteristics.
HIV infection is associated with myelosuppression, and
neutropenia occurs in up to 30% to 83% of the patients.[4,5]
Pancytopenia caused by HIV infection is multifactorial, partly
due to the effect of the infection and replication of the virus in
the myeloid progenitor cells and the cytotoxic effect of HIV
proteins.[5] Also, the deregulation of the bone marrow micro-
environment and of the production of growth factors [with
lower circulatory levels of granulocyte colony-stimulating factor
(G-CSF)] are potential causes of cytopenia.[5] Moreover, both
neutrophils and monocytes might present altered functions.[6]
Neutropenia correlates with the degree of immunosuppres-
sion[7] and constitutes a risk factor for secondary infections.
Hospitalization secondary to a bacterial infection is significantly
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neutropenia, using common terminology criteria for adverse
events version 4.0 (CTCAE v4.0)].[5] Simultaneously, cancer
treatment is a competing cause of neutropenia. Locally advanced
CC patients undergo concomitant chemoradiotherapy (CRT)
and this combination is more toxic than any of the isolated
treatments.[8] There are predefined factors that increase neutro-
penia risk, such as age, comorbidities, previous chemotherapy
(CT), active immunosuppression, creatinine clearance, aspartate
aminotransferase (AST), and pre-CT bilirubin levels.[9]
HIV infection might potentiate CRT-induced neutropenia,
which in turn can influence the course of therapy, the risk of
infection, and hospitalization. This is especially important, as
studies suggest that CC patients receiving fewer than 5 cycles of
cisplatin have a decreased overall survival (OS) when compared
with those who completed the treatment.[10,11]
A previous study concluded that HIV+ patients are less likely to
receive guideline-directed treatment for gynecological malignan-
cies,[12] while another study suggested that HIV+ patients with
CC were more likely to receive radiotherapy (RT) alone and to
develop at least 1 grade 3 to 4 CTCAE v4.0 toxicity during RT or
CRT.[13] HIV+ patients were also more prone to stop treatment
before its completion. However, this study included patients
treated with RT only or undergoing CRT with carboplatin and
this agent is known to have higher myelotoxicity than
cisplatin.[14] Nevertheless, studies in rectal, anal cancer[15–17]
and lymphoma[18] have conflicting results, with some reporting
similar rates of toxicity in HIV+ patients, while others report
increased rates, especially of myelotoxicity. Recently, the
National Comprehensive Cancer Network (NCCN) published
guidelines regarding treatment of cancer in people living with
HIV,[19] which state that CC should be treated according to the
same guidelines as patients without HIV.
If the risk of neutropenia is in fact higher in HIV+ patients, this
might influence CT completion, which seems to impact OS. A
detailed knowledge about the pattern of neutropenia incidence
and its impact on CRT completion can influence the use of
hematological support during treatment, which might reflect on
treatment outcomes.
To our knowledge, the impact of HIV infection in neutropenia
induced by cisplatin-based CRT in CC is not well characterized,
which limits informed decision making and the design of treatment
guidelines and clinical trials. Therefore, in this study, we aimed to
evaluate the impact of HIV infection in neutropenia development
duringCCtreatmentwith cisplatin-basedCRT.Wealsoanalyzed the
incidence of febrile neutropenia and hospitalization due to infection,
CT and RT completion and treatment delay due to neutropenia.
2. Methods
2.1. Study design/data source
This is a single-center retrospective cohort study. Data concerning
patients treated at Centro Hospitalar Lisboa Norte (CHLN) were
retrieved. CHLN is not only a reference-center for patients of the
Lisbon metropolitan area (referred from primary care and the
gynecological oncology multidisciplinary meeting) but also for
patients fromPortuguese-SpeakingAfricanCountries (PALOP),who
are medically referred for cancer treatments not available locally.
2.2. Patient selection/population
Consecutive women with age 18 years or older and a new
histological diagnosis of CC stage Ib-IV (by computer tomography2
and magnetic resonance imaging) treated with RT at the radiation
department and evaluated at the oncology department of CHLN
between January 2012 and December 2016 were included.
Exclusion criteria included absence of HIV testing and not having
undergone cisplatin-based CRT. HIV testing is routinely recom-
mended inPortugal forwomenwithCC, as this is anAIDS-defining
disease. Nevertheless, information on HIV testing was not
available for all patients, either reflecting absence of testing or
screening in another medical facility. Women with small cell CC
were also excluded.2.3. Study outcomes
Primary outcomes were any neutropenia event, mean absolute
neutrophil count variation, CT completion, and having received
adequate whole pelvic radiotherapy (WPRT). Secondary out-
comes included treatment delay and hospitalization due to
infection, incidence of febrile neutropenia, and total radiation
dose in conventional fractionation equivalent dose (EQD2)
[13]
assuming a/b=10Gy for the tumor. Total EQD2 included all RT
delivered in each patient including brachytherapy (BT).
Neutropenia was defined according to the CTCAE v4.0, as
neutrophil count under 2000/mm3. CT completion was defined
as having received 5 of more pre-planned cycles of cisplatin.
Adequate WPRT was defined as receiving at least 45Gy in
25 fractions.[20,21]
2.3.1. Covariates of interest. We collected demographic data,
including age, ethnicity, and disease stage at diagnosis [Interna-
tional Federation of Gynecology and Obstetrics (FIGO) 2009
staging system].We identified patients who had received previous
CT or RT. Concomitant intake of immunosuppressants, basal
bilirubin, AST, and creatinine clearance were collected. We
registered information regarding CT administration, neutrophil
count before each cycle, and cycle delay. We registered RT data
including dose and fractionation regarding external beam RT
(EBRT), BT, or external beam boost. Febrile neutropenia was
defined as the presence of fever (≥38.5°C) of unknown origin or
with microbiologically documented infection, with neutrophil
values < 1000/mm3. Regarding HIV+ patients, we also collected
data regarding ART during CRT and baseline CD4 T cell count.2.4. Treatment
2.4.1. Chemotherapy. Patients were given cisplatin 40mg/m2
(maximum 70mg/cycle) intravenously in a 500mL 0.9% sodium
chloride (NS) injection over 60minutes weekly for 6 doses,
during weeks 1 to 6 of RT. One thousand milliliters of 0.9% NS
were administeredwith 2g ofmagnesium sulfate and 20mEq/L of
potassium chloride over 90minutes, before and after cisplatin.
Antiemetic prophylaxis was given according to the European
guidelines for antiemesis in high emetogenic potential CT.[22]
Cisplatin would not be administered if serum creatinine was
> 1.5 times the upper limit of normality or if neutrophils were
 1500/mm3.
2.4.2. Radiotherapy. RT was delivered as WPRT followed by a
boost to the tumor with BT or with EBRT if BT was unfeasible
(risk of uterine perforation, anesthesia-associated risks, insuffi-
cient tumor response for BT applicator insertion, or patient
refusal). In case of hemostatic intention, a first EBRT plan was
delivered to the tumor, and a second planning-CT was acquired
for WPRT. All patients underwent a pelvic CT-scan for WPRT
EBRTwith 3mm image thickness reconstruction. Target volumes
Patients with cervical cancer treated with RT in the 
Centro Hospitalar Lisboa Norte between 01/01/2012 and 
31/12/2016: 
Cases: n=119 
Patients included n=61 (6 HIV+ and 55 HIV-) 
Exclusion criteria: (n=58) 
Not having received cisplatin-
based CT (n=14) 
No information regarding HIV 
(n=41) 
Non SCC cervical cancer 
(n=3) 
Figure 1. Study design and exclusion criteria (CONSORT).
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Units and Measurements (ICRU) Reports #50 and #62 and all
patients were treated with conformal EBRT (3D-CRT). Dose
prescription and fractionation selection was according to clinical
judgment (45–50.4Gy in 25–28 fractions).
BT patients were submitted to general anesthesia to insert
tandem and other adequate devices. ICRU #38 recommendations
were followed. High dose rate BT was delivered with an iridium-
192 source. Dose prescription and fractionation varied due to
institutional policy along the years (24Gy/4 fractions or 21Gy/3
fractions). If BT was unfeasible or considered an incomplete
treatment, patients would undergo an additional planning-CT to
plan a boost with 3D-CRT technique. Dose prescription and
fractionation were dependent of clinical judgment (9–16.2Gy in
5–9 fractions).
This project was ethically approved, complied with all local
regulations, and is in accordance with the 1964 Helsinki
declaration and its later amendments. No formal consent was
required by the ethics committee, given the nature of the study.2.5. Statistical analysis
Patients were divided into 2 cohorts. Cohort 1 included HIV+
patients and cohort 2 includedHIV 1/2 negative (HIV) patients.
Descriptive statistics of baseline demographic, clinical, patho-
logical, and treatment characteristics were performed, according
to HIV status. We tested differences in groups with Fisher exact
test or Wilcoxon rank-sum, as appropriate. The variation of
neutrophil count was evaluated in each cycle. For dichotomous
outcomes, univariate and multivariate analyses [including HIV
status, baseline AST, estimated glomerular filtration rate (eGFR),
and total EQD2 of RT] were performed using logistic regression.
Goodness of fit of the models was evaluated by the Hosmer–
Lemeshow test and ROC curves. Mixed linear models were used
to determine the effect of HIV and time on neutrophil count. Data
were analyzed using Stata v14.2 (StataCorp LLC Texas). P values
less than .05 were considered statistically significant.3. Results
3.1. Study sample and baseline characteristics
A total of 119 patients with CCwere identified, of whom 58 were
excluded; 61 were eligible for the study (Fig. 1).
Baseline demographic, clinicopathological characteristics, and
previous treatment received are summarized in Table 1. Among
the 61 patients included, 55 were HIV and 6 were HIV+. Mean
age was similar in both groups. Most HIV women were black
(65.4%; n=36), while black women represented 50.0% of HIV+
women (P= .66). Regarding the country of origin, most HIV+
patients were from Portugal (50.0%, n=3), while most HIV
patients were from Cape Verde (52.7%, n=29).
Regarding clinical stage at diagnosis, the groups were
balanced, with most patients classified with stage II-III in both
groups (P= .42; Table 1).
Most patients had not received previous CT for other
malignancy (96.3% HIV and 100% of HIV+ women). Only
12.7% (n=7) of HIV had received previous hemostatic RT for
CC, while none of the HIV+ had previous RT. No patient
received concomitant immunosuppressant medication during
CRT.
Regarding baseline characteristics, there were no differences in
univariate analysis between median bilirubin levels (P= .85) and3
eGFR (P= .13), calculated through the modification of diet in
renal disease (MDRD) formula. AST levels were significantly
higher in HIV+ women (P= .04), although within the normal
range.3.2. HIV+ population
Of the 6 HIV+ patients, 4 were under ART during CRT (2
without ART). The only patient with monotherapy was under a
non-nucleoside reverse transcriptase inhibitor (NNTRI). The
other 3 were taking combination therapy, 2 under nucleoside
reverse transcriptase inhibitors (NTRIs) and protease inhibitors
(PIs), and 1 under NTRI and integrase inhibitors (II).
Mean T CD4+ count before CRT was 567.5cells/mm3 (range
59.9–1181.6), and was significantly lower in HIV+ women who
were not under ART [mean 69.3cells/mm3, 95% confidence
interval (95% CI) -163.9 to 302.4] when compared with women
under ART (mean 747.8cells/mm3, 95% CI 271.2–1324.3;
P= .04). Regarding baseline neutrophil count, HIV+ women
without ART had mean 4255/mL, (range 1830–6680/mL) and
HIV+ women under ART hadmean 4555/mL (range 3560–5700/
mL). When analyzing different ART combinations, the patient
under NNTRI had baseline 6450cells/mm3, the patient under
NTRI and II had 8610cells/mm3, and mean count of patients
with NTRI and PI inhibitors (n=2) was 6185cells/mm3.3.3. Neutropenia
Despite the absolute differences, baseline neutrophil count
was nonsignificantly lower at baseline in HIV+ women (mean
4455/mL, range 1830–6689 vs mean 6340, range 1720–18,970
in HIV; P= .86), Table 2.
From cycles 1 to 6, neutrophil count decreased in both groups
(P< .001; Fig. 2), with neutropenia occurring in 66.7% of HIV+
patients and 36.4% of HIV patients (univariate P= .20). In the
multivariate analyses, HIV+ patients had a higher risk for the
occurrence of neutropenia [adjusted odds ratio (OR) 7.3, 95%CI
1.02–52.3; P= .05]. Model fit was appropriate [area under the
curve (AUC)=0.75].
At the end of treatment, there was a trend for lower median
neutrophil values in HIV+ women [1752/mL (IQR 1100–2930)
versus 3147/mL (IQR 920–18,390) in HIV women; P= .06],
Fig. 3.
Table 1
Demographic, clinicopathologic characteristics, and previous
treatment.
Variable list HIV negative HIV positive P
Demographic and clinicopathologic characteristics
Age, median (IQR) 47.9 (42.5–54.2) 48.0 (43.2–58.7) .86
Race, n (%)
Black 36 (65.4) 3 (50.0) .66
Caucasian 19 (34.6) 3 (50.0)
Country of origin, n (%)
Portugal 16 (29.1) 3 (50.0) .120
Cape Verde 29 (52.7) 1 (16.7)
Democratic Republic of São Tomé
and Príncipe
9 (16.4) 1 (16.7)
Guinea-Bissau 1 (1.8) 1 (16.7)
Stage, n (%)
II 28 (50.9) 2 (33.3) .42
III 22 (40.0) 3 (50.0)
IV 5 (9.1) 1 (16.7)
Basal bilirubin, median (IQR) 0.32 (0.28–0.4) 0.32 (0.22–0.4) .85
Basal AST, median (IQR) 19 (16–26) 25.5 (23–29) .04
Basal creatinine clearance
(MDRD equation), mL/min
125 (95.1–141) 93.4 (82.1–129.8) .13
Previous treatment
Previous CT for any malignancy, n (%)
No 53 (96.3) 6 (100) 1.00
Yes 2 (3.7) 0
Previous surgery for cervical cancer, n (%)
No 52 (94.6) 5 (83.3) .35
Yes 3 (5.5) 1 (16.7)
Hemostatic RT for cervical cancer, n (%)
No 48 (87.3) 6 (100) 1.00
Yes 7 (12.7) 0
CT = chemotherapy, HIV = human immunodeficiency virus, IQR = interquartile range, MDRD =
modification of diet in renal disease, RT = radiotherapy.
Table 2
Neutropenia occurrence and treatment details.





Neutropenia occurrence and management
Basal neutrophil count,
mean (range)
6340 (1720–18,970) 4455 (1830–6689) .86
End of treatment neutrophil
count mean (range)
3147 (920–18,390) 1752 (1100–2930) .06
G-CSF use, n (%)
No 48 (96.0) 3 (60.0) .04
Yes 2 (4.0) 2 (40.0)
Missing 5 1
Neutropenia occurrence (≥1 episode)
No 35 (63.6) 2 (33.3) .20
Yes 20 (36.4) 4 (66.7)
G1-2 neutropenia, n (%)
No 36 (65.5) 2 (33.3) .19
Yes 19 (34.6) 4 (66.7)
G3-4 neutropenia, n (%)
No 53 (96.4) 5 (83.3) .27
Yes 2 (3.6) 1 (16.7)
Number of cycle delays
median (IQR)
0 (0–0) 0.5 (0–2) .01
Treatment details
CT completion (≥5 cycles), n (%)
No 10 (18.2) 4 (66.7) .02
Yes 45 (81.8) 2 (33.3)
CT relative dose intensity
Mean (range)
91.3 (50–100) 79.0 (51.2–100) .15
RT total dose, EQD2
Mean (range) 70.1 (51.3–97.5) 69.6 (65.5–79.3) .67
BT, n (%)
No 31 (57.4) 4 (66.7) 1.00
Yes 23 (42.6) 2 (33.3)
Missing 1 –
EQD2 ≥ 68Gy, n (%)
No 33 (60.0) 4 (66.7) 1.00
Yes 22 (40.0) 2 (33.3)
BT = brachytherapy, CT = chemotherapy, EQD2 = biologically equivalent dose, HIV = human
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Figure 2. Variation of the mean log (neutrophil) value between cycles
according to HIV status.
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differed in both groups, we determined the interaction between
HIV status and time, but no significant difference was noted
(P= .229).
3.4. Febrile neutropenia and hospitalization due to
infection
There were no episodes of febrile neutropenia during CRT
treatment, regardless of HIV status.
There was 1 hospitalization due to active pulmonary
tuberculosis during CRT in an HIV+ woman who was not
under ART, when compared with none of the HIV women.
3.5. Chemotherapy completion
Overall, 66.7% (n=4) of the HIV+ patients received 5 or more
cycles of cisplatin when compared with 81.8% (n=45) of the
HIV patients. The lower rate of completion of at least 5 cycles of
cisplatin was significant in both the univariate (P= .02) and
multivariate analyses (OR 0.11, 95% CI 0.02–0.76; P= .02).
There was no evidence of poor fit of the model (P= .28), with an
AUC=0.66.
Moreover, HIV+ women had more CT cycle delays (median
0.5, IQR 0–2, P= .01) and were also more prone to use G-CSF
during CRT (40.0% vs 4.0% in HIV; P= .04). Mean relative
dose intensity of CT was nonsignificantly lower in HIV+ patients
(79.0%, range 51.2–100.0% vs mean 91.3%, range 50.0–
100.0% in HIV women; P= .15) (Table 2).4
Figure 3. Pre and post treatment neutrophil count according to HIV status.
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Mean total dose of external radiotherapy was 70.1Gy EQD2
(range 51.3–97.5) in HIVwomenwhen compared with 69.6Gy
EQD2 (range 65.5–79.3) in HIV+ women (P= .67). In both
groups, the majority of patients failed to receive BT (HIV+:
66.7%, n=4; HIV: 57.4%, n=31, P=1.00), Table 2. When
considering minimum WPRT dose, all patients received at least
45Gy, regardless of HIV status.
Mean duration of WPRT was significantly lower in HIV
patients, 44.7 days (range 31.0–65.0) when compared with 55.2
days (range 36.0–79.0) in HIV+ women (P= .03). Two (33.3%)
of the HIV+ women had a RT duration of more than 55 days,
when compared with 10 (18.2%) of the HIV patients.
4. Discussion
In this cohort of 61 patients, HIV+ women had a higher risk for
the occurrence of neutropenia (adjusted OR 7.3, 95% CI 1.02–
52.3) and a nonsignificant, but overall consistent trend for
decreased neutrophil counts at baseline, during, and at the end of
treatment. When considering the interaction between time and
HIV, CRT seems to induce a consistent drop of neutrophils in
both groups. Finally, this further translated into a lower rate of
chemotherapy treatment completion, more treatment delays, and
more frequent G-CSF support, but no detrimental impact on the
delivery of planned RT.
Our results are in line with those obtained by previous authors,
who concluded that more HIV+ patients experienced serious
toxicity, including leukopenia,[13] although in that cohort, HIV+
patients had a 30.6% incidence of grade 3 to 4 leukopenia when
compared with 10.2% of HIV patients (P= .04); in our study,
the incidence was lower, 16.7% (HIV+) versus 3.6% (HIV),
P= .27.[13] Nevertheless, unlike our study, that cohort also
included patients treated with RT only and treated with
carboplatin, which has a higher myelotoxicity rate than cisplatin
and this might in part account for the difference in grade 3 to 4
toxicities.[14] Also, in the same cohort study,[13] most HIV+
patients were unaware of their HIV+ status before CC diagnosis
and few were on ART before the first oncology evaluation in5
contrast to our study. This might have had an impact in the
immunological status and could relate to such higher rates of
toxicity. In fact, median CD4+ count of the HIV+ patients in that
study was 354cells/mL (range 33–1249), when compared with
mean cell count of 567.45cells/mL in our study (range: 59.9–
1181.6). We should also point out that there was a significantly
higher proportion of use of G-CSF in HIV+ patients in our
cohort, which might have contributed to a lower rate of
neutropenia, when compared with other cohorts.[13]
Nevertheless, there were no differences in both febrile
neutropenia rate and hospitalization for infection in both groups.
In our cohort,HIV+ patientswere less likely to complete 5 cycles
of cisplatin CT. However, the rate of patients who received a
minimumdose ofWPRTwas similar for both groups, aswell as the
mean EQD2 dose of RT. This supports other studies showing that
HIV+ patients tend to receive adequate RT but are less likely to
complete CT,[13] a finding also reported for HIV+ patients with
squamous cell carcinomaof the anal canal (SCCA).[15,17] In SCCA,
theCTdoses aredescribed tobe reduced (in54–66.6%ofpatients),
although sometimes these were pre-planned reductions. Similar
doses of RT are given in both HIV+ and HIV patients.[15,17]
Of note, meanWPRT duration was significantly longer in HIV
+ patients (55.2 days). Considering that 33.3% of HIV+ patients
and 42.6% of HIV patients additionally received BT, the total
duration of treatment was in fact even longer for these patients. It
is known that EBRT and BT should be completed in 55 days or
less (8 weeks), as higher duration of treatment is associated with
worse outcomes both in tumor control and OS.[23] The duration
of RT in our cohort might relate with several factors such as
noninfectious medical complications, compliance with treatment,
and technical/logistical challenges.
When considering HIV+ women only, although mean T CD4+
count at baseline was significantly lower in HIV+ women who
were not under ART (n=2), there was no difference in rates of CT
completion for those who were under ART therapy and those
without treatment during CRT, but sample size precludes us from
deriving conclusions from these results.
Despite all the methodological efforts, this study has
limitations. This is a small, single-center retrospective cohort
study. Long-term follow-up was not available due to loss of
follow-up of patients medically referred from the PALOP, given
that in these cases, further care is provided locally. Although all
patients under ART showed neutrophil counts within the normal
range at baseline, we were not able to control for the potential
myelosuppressive effects of different classes of ART drugs. Also,
the unbalanced use of G-CSF in most HIV+ patients might have
positively impacted neutrophil counts in this group, thus blunting
the effect of HIV infection. The use of G-CSF in CRT is still
controversial and most recent recommendations on its use derive
from studies in chest malignancies.[24,25] Even if neutropenia is
reversed, old reports for abdominal RT and extended field CRT
in chest malignancies stated a small number patients had severe
thrombocytopenia with the use of G-CSF.[26] This led ASCO to
recommend against use of CSFs for CRT, but these recom-
mendations are being questioned.[24,27]
In summary, we showed that HIV+ patients have a significantly
increased risk of neutropenia during CRT for CC, even while
receiving G-CSF more frequently. They are also less likely to
complete CT, while receiving similar RT dosing. These data
support the need of a careful follow-up of HIV+ patients during
CRT treatment given their increased risk for toxicity. Further
research on the impact of treatment completion on local
recurrence and survival are needed.
[11] Krusun S, Pesee M, Supakalin N, et al. Treatment interruption during
Vendrell et al. Medicine (2018) 97:30 MedicineAuthor contributions
Conceptualization: Ines Vendrell, André N. Abrunhosa-Bran-
quinho, Catarina F. Pulido, Marília Jorge, Maria Filomena de
Pina, Conceição Pinto, Luís Costa.
Data curation: Ines Vendrell, Arlindo R. Ferreira, André N.
Abrunhosa-Branquinho, Patrícia Miguel Semedo, Catarina F.
Pulido.
Formal analysis: Ines Vendrell, Arlindo R. Ferreira.
Methodology: Ines Vendrell, Arlindo R. Ferreira.
Supervision: Ines Vendrell, Arlindo R. Ferreira.
Validation: Ines Vendrell.
Writing – original draft: Ines Vendrell, Arlindo R. Ferreira, André
N. Abrunhosa-Branquinho, Patrícia Miguel Semedo, Catarina
F. Pulido, Marília Jorge, Maria Filomena de Pina, Conceição
Pinto, Luís Costa.
Writing – review & editing: Ines Vendrell, Arlindo R. Ferreira,
André N. Abrunhosa-Branquinho, Patrícia Miguel Semedo,
Catarina F. Pulido, Marília Jorge, Maria Filomena de Pina,
Conceição Pinto, Luís Costa.
References
[1] Cobucci RNO, Lima PH, de Souza PC, et al. Assessing the impact of
HAART on the incidence of defining and non-defining AIDS cancers
among patients with HIV/AIDS: a systematic review. J Infect Public
Health 2015;8:1–0.
[2] de Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to
infections among adults with HIV in the United States. AIDS 2015;
29:2173–81.
[3] Chirenje ZM. HIV and cancer of the cervix. Best Pract Res Clin Obstet
Gynaecol 2005;19:269–76.
[4] Murphy M, Metcalfe P, Waters A, et al. Incidence and mechanism of
neutropenia and thrombocytopenia in patients with human immunode-
ficiency virus infection. Br J Haematol 1987;66:337–40.
[5] Shi X, Sims MD, Hanna MM, et al. Neutropenia during HIV infection:
adverse consequences and remedies. Int Rev Immunol 2014;33:
511–36.
[6] Michailidis C, Giannopoulos G, Vigklis V, et al. Impaired phagocytosis
among patients infected by the human immunodeficiency virus:
implication for a role of highly active anti-retroviral therapy. Clin
Exp Immunol 2012;167:499–504.
[7] De Santis GC, Brunetta DM, Vilar FC, et al. Hematological abnormali-
ties in HIV-infected patients. Int J Infect Dis 2011;15:e808–11.
[8] Hu Y, Cai Z-Q, Su X-Y. Concurrent weekly cisplatin versus triweekly
cisplatin with radiotherapy in the treatment of cervical cancer: a meta-
analysis result. Asian Pacific J Cancer Prev 2012;13:4301–4.
[9] Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of
neutropenic complications in patients receiving cancer chemotherapy.
Cancer 2011;117:1917–27.
[10] Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced
cervical carcinoma: an analysis of cisplatin dosing and other clinical
prognostic factors. Gynecol Oncol 2010;116:438–41.6
concurrent chemoradiotherapy of uterine cervical cancer; analysis of
factors and outcomes. Asian Pac J Cancer Prev 2014;15:5653–7.
[12] Levinson KL, Riedel DJ, Ojalvo LS, et al. Gynecologic cancer in HIV-
infected women: treatment and outcomes in a multi-institutional cohort.
AIDS 2018;32:171–7.
[13] Simonds HM, Neugut AI, Jacobson JS. HIV status and acute
hematologic toxicity among patients with cervix cancer undergoing
radical chemoradiation. Int J Gynecol Cancer 2015;25:884–90.
[14] Go RS, Adjei AA. Review of the comparative pharmacology and clinical
actvity of cisplatin and carboplatin. J Clin Oncol 1999;17:409–22.
[15] Hammad N, Heilbrun LK, Gupta S, et al. Squamous cell cancer of the
anal canal in HIV-infected patients receiving highly active antiretroviral
therapy: a single institution experience. Am J Clin Oncol 2011;34:135–9.
[16] Grew D, Bitterman D, Leichman CG, et al. HIV infection is associated
with poor outcomes for patients with anal cancer in the highly active
antiretroviral therapy era. Dis Colon Rectum 2015;58:1130–6.
[17] Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive
patients: high-dose chemoradiotherapy is feasible in the era of highly active
antiretroviral therapy. Dis Colon Rectum 2005;48:1176–81.
[18] Housri N, Yarchoan R, Kaushal A. Radiotherapy for patients with the
human immunodeficiency virus: are special precautions necessary?
Cancer 2010;116:273–83.
[19] National Comprehensive Cancer Network (NCCN). NCCN Clinical
Practice Guidelines in Oncology. Cancer in people living with HIV
1.2018. 2010 Feb 28;National Comprehensive Cancer Network.
Available at https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf.
[20] Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized
trial comparing concurrent single agent cisplatin, cisplatin-based
combination chemotherapy, or hydroxyurea during pelvic irradiation
for locally advanced cervical cancer: a gynecologic oncology group study.
J Clin Oncol 2007;25:2804–10.
[21] Barraclough LH, Swindell R, Livsey JE, et al. External beam boost for
cancer of the cervix uteri when intracavitary therapy cannot be
performed. Int J Radiat Oncol Biol Phys 2008;71:772–8.
[22] Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO
guideline update for the prevention of chemotherapy- and radiotherapy-
induced nausea and vomiting and of nausea and vomiting in advanced
cancer patients. Ann Oncol 2016;27:v119–33.
[23] Viswanathan AN, Beriwal S, De Los Santos JF, et al. American
Brachytherapy Society consensus guidelines for locally advanced
carcinoma of the cervix. Part II: high-dose-rate brachytherapy.
Brachytherapy 2012;11:47–52.
[24] Sheikh H, Colaco R, Lorigan P, et al. Lung cancer use of G-CSF during
concurrent chemotherapy and thoracic radiotherapy in patients with
limited-stage small-cell lung cancer safety data from a phase II trial. Lung
Cancer 2011;74:75–9.
[25] Vokes EE, Haraf DJ, Drinkard LC, et al. A phase I trial of concomitant
chemoradiotherapy with cisplatin dose intensification and granulocyte-
colony stimulating factor support for advancedmalignancies of the chest.
Cancer Chemother Pharmacol 1995;35:304–12.
[26] Fyles AW,Manchul L, LevinW, et al. Effect of filgrastim (G-CSF) during
chemotherapy and abdomino-pelvic radiation therapy in patients with
ovarian carcinoma. Int J Radiat Oncol Biol Phys 1998;41:843–7.
[27] Li N, Noticewala SS, Williamson CW, et al. Feasibility of atlas-based
active bone marrow sparing intensity modulated radiation therapy for
cervical cancer. Radiother Oncol 2017;123:325–30.
